ClinicalTrials.gg
RecruitingNCT05950204Updated Jul 18, 2023

Effect of Supplementation With ω-3 Fatty Acids, Vitamin D and Calcium in Patients With Acute Lymphoblastic Leukemia.

An interventional study of ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate) in Acute Lymphoblastic Leukemia and Vitamin d Deficiency, sponsored by Coordinación de Investigación en Salud, Mexico. Recruiting at 1 site in Mexico. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-07-18.

Sponsored by Coordinación de Investigación en Salud, Mexico · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 9 months after the study started (first participant enrolled Sep 2022, registered Jul 2023).
  • Started Sep 2022; still recruiting 4 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
5 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico — 7 open to participants now, 11 under way, 4 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · Mexico.

Planned enrollment
17th of 26
40 · median 70
Started
2022
the only one that year
No phase
6 of 34
1 open now
Primary completion
2024-12
later than 1 of 10 live
Registered
28th of 34
by date
Lead sponsor
3 of 34
Coordinación de Investigación en Salud, Mexico

Among the 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2022, is one of 6 with no phase, reaches primary completion later than 1 of the 10 other live ones, and was the 28th registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

7 of the 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Mexico have not opened yet or have stopped. Only those recruiting at a site in Mexico →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 5 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma with a site in Mexico, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of supplementation with Omega 3, Vitamin D and Calcium, in a cohort of children with ALL undergoing treatment and compare changes in the concentrations of biomarkers of bone resorption (TRAP5b, CTX, and RANKL), the RANKL/OPG ratio, and biomarkers of bone formation (BALP, OC, PINP, PICP and OPG) after 6 and 12 weeks of supplementation.

Read the detailed description

In pediatric hematological patients, the administration of high and prolonged doses of corticosteroids has a negative effect on bone metabolism, causing a significant reduction in bone mineral density (BMD). Maintaining adequate levels of vitamin D (VD) and calcium is crucial for bone health, and deficiencies in these nutrients increase the risk of osteoporosis. Children with acute lymphoblastic leukemia (ALL) have been found to have a high prevalence of VD deficiency. Bone turnover markers (BTMs) are substances produced by osteoblasts and osteoclasts that provide information about the dynamic remodeling of bone. Limited research has investigated the role of BTMs in pediatric ALL patients receiving VD supplementation.

Emerging evidence suggests that long-chain ω-3 polyunsaturated fatty acids (LCPUFA-ω3) play a significant role in bone health. Consumption of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) may inhibit bone resorption and promote bone formation in humans.

Currently, there are no randomized controlled clinical trials comparing the effects of combined supplementation with LCPUFA-ω3, VD, and calcium on BTMs in children with cancer.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Vitamin d Deficiency

Keywords

  • Acute Lymphoblastic Leukemia
  • Bone Turnover Biomarkers
  • Corticosteroids
  • Bone Mineral Density
  • Long-Chain polyunsaturated fatty acids
  • n-3 fatty acids
  • Vitamin D
04

Who can participate

Ages eligible
5 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children with acute lymphoblastic leukemia in maintenance
  • authorization from both parents or legal guardian for recruiting of the child into the study with consent have been explained
  • Must be able to swallow capsules

Exclusion criteria

Exclusion Criteria:

  • Patients with acute or chronic renal failure
  • Added pathology
  • Fish
  • Down´s Syndrome
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Group A

    100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks

    Dietary Supplement: ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)

  • Active comparator
    Group B

    1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks

    Dietary Supplement: ω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)

Interventions

  • Dietary supplementω-3 polyunsaturated fatty acids (DHA and EPA), Vitamin D (cholecalciferol), Calcium (calcium carbonate)

    Drug page: CholecalciferolStudies of CholecalciferolCholecalciferol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intervention with 100 mg/kg/d of LCPUFA-ω3 with a ceiling dose of 3 g/d, + 1,000 mg of calcium/day and 4,000 IU (100 µg)/d of VD in those children \> 9 years and 20,000 UI/week = 2,857 UI/d in those \< 8 years for 6 weeks. The other group of patients will receive only the same dose of VD and calcium.

    Also known as: LCPUFA-ω3, Vitamin D, Calcium

06

What researchers measure

Primary outcomes

  1. Vitamin D status and changes in the concentrations of biomarkers of bone resorption

    After 6 weeks of supplementation, VD (1-25 hydroxyvitamin D) levels will be evaluated by liquid chromatography coupled to high-resolution mass spectrometry (Waters Acquity UPLC H-Class). The biomarkers of BTMs will be analyzed by ELISA. Parathormone, phosphorus and calcium will be assessed by spectrophotometry, and 3 LCPUFA-ω3 will be analyzed by gas chromatography.

    Time frame: at the time of the recruitment, 6 weeks of supplementation and after 6 weeks without supplementation

Secondary outcomes

  1. Concentrations of inflammatory markers (IL-6 and TFN)

    changes in the concentrations of inflammatory markers (IL-6 and TFN) in a cohort of children with ALL undergoing treatment after 3 months of supplementation with LCPUFA-ω3, VD, and calcium compared to a group receiving only calcium and VD

    Time frame: at the time of the recruitment, 6 weeks of supplementation and after 6 weeks without supplementation

07

Study locations

1 of 1 sites recruiting
  • Unit of research in Nutrition, Pediatric Hospital, Instituto Mexicano del Seguro Social
    Mexico City, 06720, Mexico
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2022 (actual). Primary completion is estimated for Dec 2024, 27 months after the start.

Of 207 non-industry interventional studies with no phase under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 66. This study's planned 27 months is below that.

Counting every sponsor, half of 214 studies reached it within 32 months; a quarter within 12 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 5, 2023
First posted
Jul 18, 2023
StartActual
Sep 10, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Jul 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05950204
Lead sponsor
Coordinación de Investigación en Salud, Mexico
Responsible party
María de Lourdes Barbosa Cortés (Associated researcher, Coordinación de Investigación en Salud, Mexico) — Principal investigator
First posted
Jul 18, 2023
Start date
Sep 10, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Jul 18, 2023

Study contacts

Maria de Lourdes Barbosa Cortés, PhD
Contact
lulubc@gmail.com
5514803521
Jorge3 Maldonado Hernandez
Contact
jormh@yahoo.com.mx
5518433131
María de Lourdes Barbosa Cortés, PhD
principal investigator · Instituto Mexicano del Seguro Social

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cholecalciferol

Start the discussion